Entera Bio Earnings Call Transcripts
Fiscal Year 2026
-
EB613, an oral anabolic peptide for osteoporosis, is advancing to a streamlined phase III trial after FDA alignment, targeting a major treatment gap between antiresorptives and injectables. The candidate aims to improve bone health for a broader patient population and offers strong pharmacoeconomic potential.
-
Experts highlighted a major treatment gap in osteoporosis due to injectable anabolic barriers, with strong demand for an oral option. EB613's phase II data show efficacy comparable to injectables, and its oral format could shift the treatment paradigm and improve patient access.
Fiscal Year 2025
-
The company is advancing a pipeline of oral peptide tablets, with lead candidate EB613 set for a global phase three osteoporosis trial starting in H1 2026. Regulatory progress, strong phase two data, and a focus on innovation position the platform for growth.
-
N-Tab technology enables oral peptide therapies, with EB613 advancing as the first oral anabolic osteoporosis treatment. Phase 2 data show strong efficacy and safety, and FDA alignment allows a pivotal phase III study. Market surveys indicate high demand for oral options and potential price advantages.
-
The company is advancing oral peptide therapeutics, with EB613 targeting osteoporosis in postmenopausal women and phase three trials planned for late 2025. Regulatory changes may allow bone mineral density as a surrogate endpoint, expediting approval. Updates on partnerships and pipeline progress are expected soon.